{"a":[{"_":"Merck, Moderna’s personalized cancer vaccine slows recurrence in phase 3, setting up approval push","$":{"href":"/biotech/merck-and-modernas-personalized-cancer-vaccine-slows-recurrence-ph-3-trial","hreflang":"en"}}]}
Phase 3positivePersonalized mRNA cancer vaccineKeytrudaPositive
AI Analysis
Summary
Merck and Moderna's personalized mRNA cancer vaccine demonstrated positive Phase 3 results, successfully slowing recurrence-free survival in high-risk skin cancer patients when combined with Keytruda, positioning the partners for an accelerated approval pathway.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Successfully lengthened recurrence-free survival when paired with Keytruda
Importance:8/10
Sentiment:
0.85
oncologymRNA vaccinepersonalized medicinePhase 3skin canceraccelerated approval pathway
Read the original article
Published by FierceBiotech on August 18, 2026 11:44 PM